Chronic Lymphocytic Leukemia

The FDA has approved acalabrutinib plus venetoclax for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dual CD19- and CD20-targeting CAR T-cell therapy was effective and had a unique safety profile in patients with relapsed/refractory CLL.

Obinutuzumab in combination with venetoclax yielded responses in chronic lymphocytic leukemia and small lymphocytic leukemia.

An ML-NMR analysis associated zanubrutinib with PFS improvements vs ibrutinib or acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

Andrew Lipsky, MD, discusses data with pirtobrutinib in relapsed/refractory CLL and the effect of its FDA approval on sequencing decisions for this disease.

Ianalumab plus ibrutinib showed promising efficacy and uMRD rates with manageable safety in a phase 1b study of patients with CLL.

Nemtabrutinib plus venetoclax showed early activity and manageable safety in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Treatment discontinuation with first-line BTK inhibitors was higher in the real-world setting vs the clinical trial setting among patients with CLL/SLL.

Mahesh Swaminathan, MB, BS, discusses whether the addition of obinutuzumab after 1 year of acalabrutinib/venetoclax is safe and effective in CLL.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

Drs Rhodes and Patel highlight how the chronic lymphocytic leukemia treatment paradigm continues to evolve with advances in targeted therapy.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends spanning CML, CLL, B-cell lymphomas, and other hematologic malignancies.

Drs Armstrong and Tawagi highlight chronic lymphocytic leukemia updates from the 2025 ASH Annual Meeting.

Pitrobrutinib monotherapy showed significant efficacy improvements in first-line CLL/SLL compared with BR treatments.

Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.

Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.

Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Pirtobrutinib yields superior overall response rates and promising progression-free survival compared with ibrutinib in chronic lymphocytic leukemia.

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.